Granocyte ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 18 | 脊髄小脳変性症（多系統萎縮症を除く。） | 1 |
| 57 | 特発性拡張型心筋症 | 2 |
18. 脊髄小脳変性症（多系統萎縮症を除く。）
臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-003084-34-GB (EUCTR) | 22/01/2018 | 28/11/2017 | Testing granulocyte-colony stimulating factor (GCSF) in patients with Friedreich Ataxia | The pharmacological effects of granulocyte-colony stimulating factor (GCSF) on frataxin expression in patients with Friedreich Ataxia - GCSF for Friedreich Ataxia | Friedreich Ataxia MedDRA version: 20.0;Level: LLT;Classification code 10003592;Term: Ataxia cerebellar;System Organ Class: 100000004852 MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Granocyte Product Name: Granocyte INN or Proposed INN: rHuG-CSF Other descriptive name: Lenograstim | University of Bristol | NULL | Not Recruiting | Female: Male: | 7 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |
57. 特発性拡張型心筋症
臨床試験数 : 11 / 薬物数 : 23 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01302171 (ClinicalTrials.gov) | August 2010 | 21/2/2011 | Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy | Randomised Controlled Trial to Compare the Effects of G-CSF (Granocyte™) and Autologous Bone Marrow Progenitor Cells on Quality of Life and Left Ventricular Function in Patients With Idiopathic Dilated Cardiomyopathy | Dilated Cardiomyopathy | Drug: granulocyte colony stimulating factor (GCSF);Procedure: bone marrow mononuclear cells | Barts & The London NHS Trust | Royal Brompton & Harefield NHS Foundation Trust;University College London Hospitals | Completed | 18 Years | 80 Years | Both | 60 | Phase 2 | United Kingdom |
| 2 | EUCTR2009-013112-12-GB (EUCTR) | 22/04/2010 | 17/03/2010 | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dilated Cardiomyopathy - REGENERATE-DCM | Idiopathic Dilated Cardiomyopathy Level: LLTClassification code 10056419Term: Dilated Cardiomyopathy | Trade Name: Granocyte Lenograstim Product Name: GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) Product Code: PL 12185/0002 & PL 12185/0005(WATER FOR INJECTION) | Barts & the London NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom |